Every Form 4 that Oragenics Inc. (OGEN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OGEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OGEN filings page.
Oragenics Inc reported that its Chief Financial Officer, John Spencer, received a grant of stock options. The award covers 55,900 options to buy Oragenics common stock at an exercise price of $0.59 per share under the company’s 2021 Equity Incentive Plan.
According to the terms, one fifth of the options vest on the grant date, with the remaining options vesting in equal annual installments on the first through fourth anniversaries of the grant date, contingent on continued service. Following this grant, Spencer holds 55,900 derivative securities related to this award, which expire on July 1, 2036. The filing shows no open-market purchases or sales of common stock.
Oragenics, Inc. director Fred Telling filed an amended insider trading report covering a small stock sale and a new option grant. On 12/12/2025, he sold 210 shares of common stock at a weighted average price of $0.9446, and held 948 shares directly after the transaction. The filing notes that the shares were sold in multiple trades between $0.9440 and $0.9451.
The amendment also reports a grant of 125,000 non-employee director stock options on 12/11/2025 with an exercise price of $0.93 per share, vesting immediately and expiring on 12/11/2035. The company previously completed a 1-for-30 reverse stock split of its common stock, and this amendment corrects the amount of securities beneficially owned to reflect that corporate action.
Oragenics, Inc. reported an equity award to its CEO and CFO, Janet Huffman. On 12/11/2025 she was granted an employee stock option to buy 250,000 shares of Oragenics common stock at an exercise price of $0.93 per share under the Company's 2021 Equity Incentive Plan, as amended.
One third of the options vest on the first anniversary of the grant date, with the remaining two thirds vesting in equal annual installments on the second and third anniversaries, provided she continues to perform services for the company through each vesting date. The options are scheduled to expire on 12/11/2035, and the exercise price was set at the closing price of the common stock on the grant date.
Oragenics Inc. reported that director Natasha Giordano received two stock option awards under the company’s 2021 Equity Incentive Plan on December 11, 2025. One non-employee director option covers 38,320 shares of common stock at an exercise price of $1.03, granted as an initial equity award upon her appointment to the board, and it vests immediately. A second option covers 125,000 shares at an exercise price of $0.93, also under the non-employee director compensation program, and it vests immediately as well. Both option grants are exercisable from December 11, 2025 and expire on December 11, 2035, and are held directly.
Oragenics Inc. director Fred Telling reported a small sale of company stock and a new stock option grant. On 12/12/2025, he sold 210 shares of common stock at a weighted average price of $0.9446 per share, leaving him with 34,538 shares of Oragenics common stock held directly.
On 12/11/2025, he received a non-employee director option award for 125,000 shares of Oragenics common stock under the company’s 2021 Equity Incentive Plan. The options have an exercise price of $0.93 per share, vest immediately on the grant date, and are scheduled to expire on 12/11/2035.
Oragenics Inc (OGEN) reported a grant of non-employee director stock options to director John Gandolfo. On 12/11/2025 he received options to purchase 125,000 shares of common stock at an exercise price of $ 0.93, with an expiration date of 12/11/2035.
The award was made under Oragenics' 2021 Equity Incentive Plan, as amended, pursuant to its non-employee director compensation program. The options vest immediately, and Gandolfo beneficially holds 125,000 derivative securities directly following this transaction.
Oragenics director Alan Dunton reported receiving an award of 125,000 options to buy the company’s common stock at an exercise price of $0.93 per share on 12/11/2025.
The options were granted under the company’s 2021 Equity Incentive Plan, as amended, pursuant to its non-employee director compensation program. They vest immediately, are exercisable starting 12/11/2025, and expire on 12/11/2035. Following this grant, 125,000 derivative securities are beneficially owned directly.
Oragenics Inc reported that director Robert Koski received a grant of stock options on 12/11/2025 under the company's 2021 Equity Incentive Plan, as amended, pursuant to its non-employee director compensation program. The option covers 125,000 shares of common stock at an exercise price of $0.93 per share, equal to the closing price on the grant date. The options vest immediately, are exercisable starting 12/11/2025, and expire on 12/11/2035. Following this award, Koski beneficially owns 125,000 stock options directly.
Oragenics Inc. reported that director Charles Pope received an award of stock options as part of the company’s non-employee director compensation program. On 12/11/2025 he was granted options to buy 125,000 shares of common stock at an exercise price of $0.93 per share under the company’s 2021 Equity Incentive Plan, as amended.
The options vest immediately, making them fully exercisable from the grant date, and they expire on 12/11/2035. After this grant, Pope beneficially owns 125,000 derivative securities directly, each representing the right to purchase one share of Oragenics common stock.